Individualized Tamoxifen Dose Escalation-Response
- PMID: 27980025
- PMCID: PMC8330639
- DOI: 10.1158/1078-0432.CCR-16-2351
Individualized Tamoxifen Dose Escalation-Response
Conflict of interest statement
Disclosures: No potential conflicts of interest
Comment on
-
Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.Clin Cancer Res. 2016 Jul 1;22(13):3121-3. doi: 10.1158/1078-0432.CCR-16-0370. Epub 2016 Mar 24. Clin Cancer Res. 2016. PMID: 27012810 Free PMC article.
-
Individualized Tamoxifen Dose Escalation-Letter.Clin Cancer Res. 2016 Dec 15;22(24):6300. doi: 10.1158/1078-0432.CCR-16-1967. Clin Cancer Res. 2016. PMID: 27980024 No abstract available.
References
-
- Lintermans A, Van Asten K, Jongen L, Blomme C, Lambrechts D, Van Calster B, et al. Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting. ASCO Meeting Abstracts 2016;34(15_suppl):523.
-
- Stearns V, O’Neill AM, Schneider BP, Flockhart DA, Skaar TC, Liu MC, et al. A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. ASCO Meeting Abstracts 2016;34(15_suppl):546.
-
- Isaacs D, Fitzgerald D. Seven alternatives to evidence-based medicine. Oncologist 2001;6(4):390–1. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources